Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Liotta

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
Clinical and Experimental Immunology|June 1, 2021
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2-year real-life experienceEmanuele Vivarelli, Andrea Matucci, Susanna Bormioli, et al.
Experimental Cell Research|March 11, 2008
MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cellsKrista Rombouts, Benedetta Lottini, Alessandra Caligiuri, et al.
The Journal of Experimental Medicine|August 7, 2002
Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytesFrancesco Annunziato, Lorenzo Cosmi, Francesco Liotta, et al.
Immunotherapy|February 13, 2020
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patientsMelissa Bersanelli, Stefania Scala, Paola Affanni, et al.
The Journal of Allergy and Clinical Immunology|July 3, 2007
Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individualsLaura Maggi, Veronica Santarlasci, Francesco Liotta, et al.
Clinical Rheumatology|April 20, 2010
Kimura's disease: case report of an Italian young male and response to oral cyclosporine A in an 8 years follow-upEnrico Beccastrini, Giacomo Emmi, Michela Chiodi, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2003
The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cellsFrancesca Brugnolo, Salvatore Sampognaro, Francesco Liotta, et al.
Frontiers in Immunology|June 14, 2018
Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's SyndromeAndrea Matucci, Francesco Liotta, Emanuele Vivarelli, et al.
International Archives of Allergy and Immunology|December 22, 2012
CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapyLaura Maggi, Manuela Capone, Francesco Giudici, et al.
Frontiers in Immunology|March 25, 2026
Modulation of type 2 inflammation during grass pollen-specific sublingual immunotherapyLorenzo Salvati, Manuela Capone, Alessio Mazzoni, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
Clinical and Experimental Immunology|June 1, 2021
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2-year real-life experienceEmanuele Vivarelli, Andrea Matucci, Susanna Bormioli, et al.
Experimental Cell Research|March 11, 2008
MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cellsKrista Rombouts, Benedetta Lottini, Alessandra Caligiuri, et al.
The Journal of Experimental Medicine|August 7, 2002
Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytesFrancesco Annunziato, Lorenzo Cosmi, Francesco Liotta, et al.
Immunotherapy|February 13, 2020
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patientsMelissa Bersanelli, Stefania Scala, Paola Affanni, et al.
The Journal of Allergy and Clinical Immunology|July 3, 2007
Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individualsLaura Maggi, Veronica Santarlasci, Francesco Liotta, et al.
Clinical Rheumatology|April 20, 2010
Kimura's disease: case report of an Italian young male and response to oral cyclosporine A in an 8 years follow-upEnrico Beccastrini, Giacomo Emmi, Michela Chiodi, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2003
The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cellsFrancesca Brugnolo, Salvatore Sampognaro, Francesco Liotta, et al.
Frontiers in Immunology|June 14, 2018
Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's SyndromeAndrea Matucci, Francesco Liotta, Emanuele Vivarelli, et al.
International Archives of Allergy and Immunology|December 22, 2012
CD4+CD161+ T lymphocytes infiltrate Crohn's disease-associated perianal fistulas and are reduced by anti-TNF-α local therapyLaura Maggi, Manuela Capone, Francesco Giudici, et al.
Frontiers in Immunology|March 25, 2026
Modulation of type 2 inflammation during grass pollen-specific sublingual immunotherapyLorenzo Salvati, Manuela Capone, Alessio Mazzoni, et al.
Pageof 11